Seeking Alpha·18h ago
Royalty Pharma plc (RPRX) Presents at Bank of America Global Healthcare Conference 2026 TranscriptRoyalty Pharma plc (RPRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Royalty Pharma's core royalty model generates robust cash flows, with revenue growing 16.5% year-over-year in 2026Q2 and operating cash flow consistently exceeding net income (OCF/NI ratio of 80.9x in 2026Q2). However, the company's aggressive debt-funded acqu...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue grew 16.5% year-over-year to $674.1M in 2026Q2, but gross margin dipped to 60.2% from near-100% levels, and net income fell 42.9% year-over-year to $17.9M, reflecting significant non-operating losses.
Royalty Pharma reported robust Q1 2026 results with 10% YoY growth in portfolio receipts and raised full-year 2026 guidance, indicating strong financial health.
The company holds a diversified portfolio of 35+ marketed therapies and 15+ development-stage assets, reducing risk and providing stable cash flows.
Royalty Pharma's asset-light model provides exposure to pharmaceutical upside without the inherent risks of R&D, making it a resilient investment.
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 5, 2026 | $1.32+3.9% vs $1.27 | $773M+1.9% vs $759M |
Q2 2026 May 6, 2026 | $1.30+7.4% vs $1.21 | $925M+4.9% vs $882M |
Q1 2026 Feb 11, 2026 | $1.46+13.2% vs $1.29 | $874M+8.3% vs $807M |
Q4 2025 Nov 5, 2025 | $1.17+17.7% vs $0.99 | $609M-15.1% vs $717M |
Royalty Pharma plc (RPRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
NEW YORK and WASHINGTON, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma and Blood Cancer United today announced a $7.5 million donation from Royalty Pharma to support Blood Cancer United's Therapy Acceleration Program (TAP), a collaborative venture philanthropy initiative designed to accelerate the development of promising blood cancer therapies through strategic equity investments and hands-on collaboration with biotech companies.
Royalty Pharma plc (RPRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of September:
Benchmark RPRX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Royalty Pharma plc (RPRX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $57.65 | $25.55B | 32.03 | 5.06% | 32.42% | 7.69% | 1.17% | |
| $26.39 | $3.32B | -8.02 | -4.26% | -386.32% | -87.98% | — | |
| $36.07 | $6.76B | 32.50 | 47.52% | 78.04% | 19.57% | — | |
| $145.45 | $66.05B | 44.21 | 83.33% | 64.66% | 22.96% | — | |
| $252.78 | $21.45B | 37.78 | 44.57% | 47.7% | 11.48% | — | |
| $260.91 | $50.32B | 44.52 | 63.69% | 63.79% | 19.08% | — |
Royalty Pharma plc (RPRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Royalty Pharma plc (RPRX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 5, 2026·SEC
Jun 4, 2026·SEC
May 28, 2026·SEC
Get notified when RPRX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Royalty Pharma plc (RPRX) stock FAQ — growth, dividends, profitability & financials explained
Royalty Pharma plc (RPRX) reported $2.54B in revenue for fiscal year 2025. This represents a 59% increase from $1.60B in 2017.
Royalty Pharma plc (RPRX) grew revenue by 5.1% over the past year. This is steady growth.
Yes, Royalty Pharma plc (RPRX) is profitable, generating $815.3M in net income for fiscal year 2025 (32.4% net margin).
Yes, Royalty Pharma plc (RPRX) pays a dividend with a yield of 1.17%. This makes it attractive for income-focused investors.
Royalty Pharma plc (RPRX) has a return on equity (ROE) of 7.7%. This is below average, suggesting room for improvement.
Royalty Pharma plc (RPRX) generated $3.74B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
